The Importance of the Immunosuppressive Regime on Hepatocellular Carcinoma Recurrence After Liver Transplantation

Basit Öğe Kaydı
dc.authoridince, volkan/0000-0002-0714-490X
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authorwosidince, volkan/M-7325-2017
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.contributor.authorYilmaz, Sezai
dc.contributor.authorInce, Volkan
dc.date.accessioned2024-08-04T20:50:44Z
dc.date.available2024-08-04T20:50:44Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose Hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) occurs in approximately 20% of recipients and these patients have median about one year survival after diagnosis. Some immunosuppressive drugs can cause development of HCC recurrence, on the other hand some immunosuppressive drugs may have a positive effect for preventing HCC recurrence. Thus, immunosuppression (IS) modification may play a role in preventing HCC recurrence. Methods In this review, we analyzed IS treatment strategy in two parts: before HCC recurrence following LT and after HCC recurrence following LT, and after HCC recurrence following LT. Results There is no proven, optimal IS protocol to prevent HCC recurrence after transplantation. Therefore, individualized immunosuppressive treatments should be tailored to the biological behaviour of HCC. Forcing the immune tolerance in terms of recurrence can probably be expressed as the most appropriate post LT period. Once HCC recurrence has developed after transplantation, again, there is no commonly accepted, optimal IS treatment, but there is a tendency to switch to IS modifications that include mTORi by minimizing CNIs and MMF. Conclusion There is a need for well-designed, randomized, controlled clinical studies with larger numbers of patients on this subject.en_US
dc.identifier.doi10.1007/s12029-021-00716-9
dc.identifier.endpage1355en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue4en_US
dc.identifier.pmid34611833en_US
dc.identifier.scopus2-s2.0-85116493236en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1350en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-021-00716-9
dc.identifier.urihttps://hdl.handle.net/11616/100248
dc.identifier.volume52en_US
dc.identifier.wosWOS:000703826900002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmunosuppressiveen_US
dc.subjectProtocolen_US
dc.subjectRelapseen_US
dc.subjectMalignen_US
dc.subjectHepatomaen_US
dc.subjectHepaticen_US
dc.subjectLiver transplantationen_US
dc.subjectHCCen_US
dc.titleThe Importance of the Immunosuppressive Regime on Hepatocellular Carcinoma Recurrence After Liver Transplantationen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu